Development of the PPMX-T004 ADC and licensing to FUJIFILM
First written in FY2021. 12 of 21 entries say "Advanced", first in FY2022. Latest entry: 2026-08-13.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「The Company is currently conducting a preliminary toxicity study and expects to determine the balance between efficacy and toxicity by September 2026.」
PPMX-T004 is continuing its preliminary toxicity study, with the timing for determining the balance between efficacy and toxicity specified as no later than September 2026. - FY2025SoftenedAnnual report
「The Company identified the optimal combination of the latest drug and the linkers used to attach it to the PPMX-T004 antibody, and confirmed high antitumor activity in mouse studies. In response, the Company is currently conducting a preliminary toxicity study. Optimization of the balance between efficacy and toxicity is expected to take place in or after the fiscal year ending March 2026.」
PPMX-T004 has progressed to preliminary toxicity studies, but optimization of the balance between efficacy and toxicity is expected in or after the fiscal year ending March 2026. - FY2025-H1SoftenedAnnual report
「The Company is currently conducting a preliminary toxicity study in monkeys, but determining the combination that optimizes the balance between efficacy and toxicity is taking longer than initially expected. The combination is expected to be determined in the next fiscal year.」
PPMX-T004 progressed to a preliminary toxicity study in monkeys, but determination of the combination based on the balance between efficacy and toxicity was delayed beyond initial expectations, and the determination is now expected in the next fiscal year. - FY2024AdvancedAnnual report
「The Company is studying the optimal combination of the latest drug and the linkers used to attach it, and the promising combinations identified in vitro showed high antitumor activity in mouse studies. The Company is currently conducting a preliminary toxicity study in monkeys.」
PPMX-T004 progressed to the stage of conducting a preliminary toxicity study in monkeys after antitumor activity was confirmed in mice. - FY2024-Q2AdvancedAnnual report
「The Company is studying the optimal combination of the latest drug and the linkers used to attach it, and the promising combinations identified in vitro showed high antitumor activity in mouse studies. In response, the Company conducted a preliminary toxicity study in rats and is also preparing a toxicity study in monkeys.」
For PPMX-T004, antitumor activity of promising combinations was confirmed in vitro and in mouse studies, and the program progressed through the implementation of a preliminary toxicity study in rats and preparations for a toxicity study in monkeys. - FY2024-Q1AdvancedAnnual report
「Promising combinations have been identified in vitro, and some have also shown efficacy in animal studies, which are continuing for validation.」
For PPMX-T004, some promising combinations of drugs and linkers showed efficacy in animal studies, and the program has advanced to the validation stage. - FY2023AdvancedAnnual report
「The Company is currently studying the optimal combination of the latest drug and the linkers used to attach it. Promising combinations have been identified in vitro, and the Company plans to validate them in animal studies.」
For PPMX-T004, promising combinations were identified in drug and linker optimization studies, and validation through animal studies is planned as the next step. - FY2023-Q3RestatedAnnual report
「PPMX-T004 is an ADC targeting CDH3. The Company is currently studying the optimization of the latest drug and the linkers used to attach it.」
For PPMX-T004, optimization studies of the drug, linkers and related components are continuing as part of its development as a CDH3-targeting ADC. - FY2023-Q2AdvancedAnnual report
「The Company is currently studying the optimization of the latest drug and the linkers used to attach it.」
For PPMX-T004, development has progressed from basic studies of the drug and linkers to optimization studies of the latest drug, linkers and related components. - FY2023-Q1AdvancedAnnual report
「PPMX-T004 is an antibody-drug conjugate (ADC) targeting CDH3 and carrying a drug. Because it targets the same target as PPMX-T002, the license for this pipeline was also returned by Fujifilm, and basic studies are currently under way on the drug and the linkers used to attach it.」
Following the return of the license, PPMX-T004 has moved into the redevelopment stage, with basic studies under way on the drug, linkers and related components. - FY2022AdvancedAnnual report
「The license for PPMX-T004 was returned to the Company in March 2022 following a change in the business policy of Fujifilm Corporation, the licensee, and the Company will proceed with its development as a new drug candidate.」
The license for PPMX-T004 was returned by the licensee, and the program moved to the stage of development by the Company as a new drug candidate. - FY2022-Q3RestatedAnnual report
「PPMX-T004 targets the same CDH3 as PPMX-T002 and is based on the concept of an antibody-drug conjugate (ADC) carrying a drug.」
Reconfirms the concept of developing PPMX-T004 as an ADC targeting CDH3. - FY2022-Q2RestatedAnnual report
「PPMX-T004 targets the same CDH3 as PPMX-T002 and is based on the concept of an antibody-drug conjugate (ADC) carrying a drug.」
Reconfirms the concept of developing PPMX-T004 as an ADC targeting CDH3. - FY2022-Q1RestatedAnnual report
「PPMX-T004 targets the same CDH3 as PPMX-T002 and is based on the concept of an antibody-drug conjugate (ADC) carrying a drug.」
Reconfirms the development concept of an ADC targeting CDH3. Its development status remains undisclosed under the agreement with the licensee. - FY2021First statedAnnual report
「PPMX-T004 targets CDH3, which is highly expressed on the surface of solid-tumor cells, and uses an antibody with high internalization into cancer cells.」
It is an antibody-drug conjugate targeting CDH3 and has already been out-licensed to Fujifilm, but its development status is undisclosed under the agreement.